New $250M Iceland Factory Puts Alvogen in Biosimilar Race

Iceland is joining the race to make generic versions of complex biotech drugs with an investment of $250 million in development and manufacturing by Alvotech, a sister company of privately owned U.S.-based Alvogen.

The money will pay for a 11,800 square meter facility in Iceland that will open in early 2016. The company hopes to have its own biosimilars in the market by 2018 when patents for a number of high-priced biologic drugs will be rolling off.

Read the Rueters press release

More News:

All news »

What are your comments?

You cannot post comments until you have logged in. Login Here.

Comments

No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments